Paraoxonase gene polymorphism and serum activity in progressive IgA nephropathy

Journal of Nephrology

Volumn 19, Issue 6, 2006, Pages 732-738

  Kovács, Tibor J ^a,b   Harris, Shelley ^b   Vas, Tibor K ^b   Seres, Ildikó ^c   Short, Colin D ^b   Wittmann, István K ^a   Paragh, György ^c   Mackness, Michael I ^d   Mackness, Bharti ^d   Durrington, Paul N ^d   Nagy, Judit M ^a   Brenchley, Paul E C ^b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Gene polymorphism; HDL; IgA nephropathy; Lipids; Paraoxonase; Progression

Indexed keywords

ARYLDIALKYLPHOSPHATASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN A; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ARYLDIALKYLPHOSPHATASE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; GLOMERULONEPHRITIS, IGA; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33947215662     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987; 64: 709-27.
2. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42.
3. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005; 18: 503-12.
4. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 1991; 31: S29-34.
5. Keane WF. Lipids and the kidney. Kidney Int 1994; 46: 910-20.
6. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 1908-15.
7. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-4.
8. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-90.
9. Mackness MI, Arrol S, Abbott CA, Durrington PN. Is paraoxonase related to atherosclerosis. Chem Biol Interact 1993; 87: 161-71.
10. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.
11. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997; 99: 62-6.
12. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-6.
13. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001; 11: 77-84.
14. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-7.
15. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-9.
16. Letellier C, Durou MR, Jouanolle AM, Le Gall JY, Poirier JY, Ruelland A. Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab 2002; 28 (4 Pt 1): 297-304.
17. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression, Am J Hum Genet 2001; 68: 1428-36.
18. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002; 22: 1329-33.
19. Blatter-Garin MC, Kalix B, De Pree S, James RW. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia 2003; 46: 593-4.
20. Gouedard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol 2003; 63: 945-56.
21. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
22. Dantoine TE Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998; 9: 2082-8.
23. Szelestei T, Bahring S, Kovacs T, Vas T, Salamon C, Busjahn A, Luft FC, Nagy J. Association of a uteroglobin polymorphism with rate of progression in patients with IgA nephropathy. Am J Kidney Dis 2000; 36: 468-73.
24. Paragh G, Asztalos L, Seres I, Balogh Z, Locsey L, Karpati I, Matyus J, Katona E, Harangi M, Kakuk G. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 1999; 83: 126-31.